Key Dates
6 May 2008
Notification of Acceptances
26 May 2008
Early Registration Cut-off Date
9 June 2008
Late breaking Abstract Submission Date
2 July 2008
Pre & Post Congress Tours
2 July 2008
Social Program Bookings
2 July 2008
Congress Day Tours
9 July 2008
Accommodation Bookings
9 July 2008
Accommodation Deposit deadline
9-10 August 2008
Postgraduate Weekend Courses
10-14 August 2008
Congress Opens
With thanks to
Prof. Hermann Einsele
Curriculum vitae
- 1977 - 1984 Eberhard-Karls-Universität Tübingen Lord Owens University Manchester Guy´s Hospital (Imperial College) London
- 1984 - 87 Research Fellow, Department of Haematology/Oncology/ Rheumatology/Immunology, University of Tübingen
- 1986
MD Thesis: Membrane alterations of red bloods cells in liver disease (summa cum laude)
1988 Fellow Max-Planck-Institute for Biochemistry, Martinsried - 1989 - 1996
Member of the Research Network SFB 120 (Immunogenetics and Allo-SCT)
- 1991
Board Certificate: Internal Medicine
- 1992 Assistant Professor
- 1993 Consultant for Internal Medicine
since
- 1993 Member of ASH, EBMT, EBMT working parties Infectious Disease and Chronic Leukemia
since
- 1995 Head of the Allogeneic Stem Cell transplantation Programme
1996 Board Certificate: Hematology/Oncology
since
- 1997 Member of the SFB 510 (Stem cell transplantation and Antigen Processing)
since 1999 Associate Professor since 1999 Chairman of the German Study Group Multiple Myeloma (DSMM)
- 12/1999 Visiting Professor FHCRC, Seattle
- 12/2000 Visiting Professor City of Hope Hospital, Duarte
- 6/2000 Member of the Board of the German Society of Stem Cell Transplantation (DAG-KBT)
- 7/2003 van Bekkum- Award European Society of Blood and Marrow Transplantation
- 4/2004 Chairman of the Infectious Disease Working Party of the EBMT
Member of the European Myeloma Net
Board of the European Blood and Marrow Transplantation Society
Member of the Board of the German Lymphoma NetWork
- 12/2004 Director of Medizinische Klinik und Poliklinik II Bavarien Julius-Maximilians-University, Würzburg
Research Activities:
- Multiple Myeloma
- Immune reconstitution after Stem Cell Transplantation/GvHD (SFB 120 1988-1996)
Local virus infections and associated Cytokine Dysregulation in Autoimmune Diseases (BMBF 1988-1994)
- Herpes Virus Infections in Transplantation
(BMBF 1993- 2000)
- Molecular Diagnostics for Fungal Infection
(Fortüne-Programme, Krebshilfe, 1998)
- Adoptive T cell therapy after Stem Cell Transplantation
(SFB 510)
- National Genome Network (TübinGenom)
Genetic epidemiology of invasive Aspergillosis
- EU, FP6 Integreated Project: Allostem:
Immunotherapy for CMV/EBV infection
- EU FP6 NoE Euronet-Leukemia "Supportive Care"
- Jose-Carreras-Foundation
Genetically modified T cells to combat Myeloma cells
- EU FP6 MANASP "Development of Novel Management strategies for invasive aspergillosis"
- DFG SFB 479: Immune regulation in CMV infection
- DFG SFB 1160: Host-Pathway Interaction in IA
Dr Geoffrey Hill
Geoff Hill obtained his undergraduate and medical degree at the University of Auckland. His specialist Haematology training was undertaken in Christchurch, NZ, The Dana Farber Cancer Institute, and Harvard Medical School in Boston.
His doctoral thesis is based on work at Harvard University where he characterized the mechanisms by which BMT conditioning influences acute GVHD and developed therapeutic interventions to inhibit this pathogenic pathway. This work provided the rationale for studies of low intensity conditioning and new growth factors (especially KGF) in myeloablative transplantation which have now moved through successful phase III clinical trials in the USA and onto the market.
Dr Hill is a NH&MRC Practitioner Fellow with his own laboratory at the Queensland Institute of Medical Research. His focus is currently on the interactions between growth factors, antigen presenting cells and NKT / regulatory T cells during transplantation. This has led to the study of new growth factors for the mobilization of hematopoietic stem cells to improve leukemia clearance after transplantation. Dr Hill was named the 2005 “Queenslander of the year” for his basic research and clinical work in transplant field.
Dr Megan Sykes
Megan Sykes is the Harold and Ellen Danser Professor in the Department of Surgery and Professor of Medicine (Immunology) at Harvard Medical School. She is an Immunologist at Massachusetts General Hospital, and Associate Director of the Transplantation Biology Research Center. She is the Immediate Past President of the International Xenotransplantation Association and is Vice President of The Transplantation Society.
Dr. Sykes' research is in the areas of hematopoietic cell transplantation, achievement of graft-versus-leukemia effects without GVHD, organ allograft tolerance induction and xenotransplantation. Her research program aims to utilize bone marrow transplantation as immunotherapy to achieve graft-versus-tumor effects while avoiding the common complication of such transplants, graft-versus-host disease. Her laboratory studies in this area have led to novel approaches that have been evaluated in clinical trials at MGH. Another major area of her research has been to utilize bone marrow transplantation for the induction of transplantation tolerance, both to organs from the same species (allografts) and from other species (xenografts). Her laboratory has worked toward the development of clinically feasible, non-toxic methods of re-educating the T cell, B cell and NK cell components of the immune system to accept allografts and xenografts without requiring long-term immunosuppressive therapy. Her work has also extended into the area of xenogeneic thymic transplantation as an approach to tolerance induction, and into the mechanism by which non-myeloablative induction of mixed chimerism reverses the autoimmunity of Type 1 diabetes.
Return to the State of The Art Program
